Neutrahealth Share Discussion Threads

[diogenesj] 29/5/2007 12:16

Thanks for that, Shanklin. It seems to have given the shares a kick.

[quotes_4_u] 29/5/2007 10:09

That tip has put this stock on the map !

And with a 17 million market cap after the current rise it's hardly
expensive given the forcasts and the growth.

Picked some up this morning, due to a large seller the price has not
raced away first thing so nice to take advantage and get some on the
cheap.

[eggbird] 29/5/2007 08:05

Looks good, I managed to grab a few, but my trade isn't showing up yet.

[shanklin] 29/5/2007 07:28

Not sure which is the current thread, so here's something I posted on the other thread...

Nice piece in the Mail on Sunday

Cheers, Martin



"Nutraceuticals may sound like the latest robo-toy for spoilt six-year-olds, but it is actually one of the fastest-growing parts of the food and health market.

The sector comprises four elements: organic food; functional food, such as Actimel yogurts or cereal bars; vitamins, minerals and other supplements; and alternative items, such as aromatherapy products.

The market turned over almost £2.5bn last year and the figure should be substantially higher in 2007. Yet the sector is highly fragmented, consisting largely of small businesses.

NeutraHealth wants to change that. The company was set up in 2004 and joined Aim the following year with the express intention of creating a national leader in the nutraceutical sector.

The group has made three acquisitions so far and has launched two brands of its own, Champneys and Travelguard, which are sold in chains such as Boots and Holland & Barrett.

Champneys and Travelguard use some of the expertise from Neutrahealth's recently acquired businesses to make products that are said to apply genuine science to a variety of issues. Travelguard, for instance, offers a product designed to reduce the chances of getting a stomach upset overseas.

NeutraHealth has an impressive board, including Sir Gulam Noon, who built one of the biggest Indian food manufacturers in Britain, Noon Products.

NeutraHealth made profits of £900,000 last year on turnover of £8.6m. Profits are expected to hit £3m in 2007 and chief executive Michael Toxvaerd hopes to increase turnover to £50m over the next few years.

•• Midas verdict: NeutraHealth shares are trading at 10¾p. The company is operating in a burgeoning sector and its directors are keen to capitalise. A lot of pseudoscience exists in this field, but NeutraHealth boasts genuine scientists on its books and this should help distinguish its products as consumers become increasingly savvy about food and health. Buy and hold."

[waldiman] 28/5/2007 21:33

As an ethical investor I cannot invest here, as I am allergic to nuts.

LOL!

[shanklin] 28/5/2007 08:58

Nice piece in the Mail on Sunday

Cheers, Martin



"Nutraceuticals may sound like the latest robo-toy for spoilt six-year-olds, but it is actually one of the fastest-growing parts of the food and health market.

The sector comprises four elements: organic food; functional food, such as Actimel yogurts or cereal bars; vitamins, minerals and other supplements; and alternative items, such as aromatherapy products.

The market turned over almost £2.5bn last year and the figure should be substantially higher in 2007. Yet the sector is highly fragmented, consisting largely of small businesses.

NeutraHealth wants to change that. The company was set up in 2004 and joined Aim the following year with the express intention of creating a national leader in the nutraceutical sector.

The group has made three acquisitions so far and has launched two brands of its own, Champneys and Travelguard, which are sold in chains such as Boots and Holland & Barrett.

Champneys and Travelguard use some of the expertise from Neutrahealth's recently acquired businesses to make products that are said to apply genuine science to a variety of issues. Travelguard, for instance, offers a product designed to reduce the chances of getting a stomach upset overseas.

NeutraHealth has an impressive board, including Sir Gulam Noon, who built one of the biggest Indian food manufacturers in Britain, Noon Products.

NeutraHealth made profits of £900,000 last year on turnover of £8.6m. Profits are expected to hit £3m in 2007 and chief executive Michael Toxvaerd hopes to increase turnover to £50m over the next few years.

•• Midas verdict: NeutraHealth shares are trading at 10¾p. The company is operating in a burgeoning sector and its directors are keen to capitalise. A lot of pseudoscience exists in this field, but NeutraHealth boasts genuine scientists on its books and this should help distinguish its products as consumers become increasingly savvy about food and health. Buy and hold.

[takeatip] 27/5/2007 14:12

Likewise reasoning seems good price has dropped over the last couple of years so could be a good recovery. Will reasearch a bit more before investing.

[gazwenn] 27/5/2007 10:50

this has been tipped in the Mail on Sunday. So i now have this one on my radar. What are the general thoughts on this comany?

[electric sheep] 02/5/2007 14:31

cheers wig

[wiganer] 02/5/2007 14:29

No gags about being a NUT please.

[homewell] 30/4/2007 22:39

more good news to add to the already steady flow, and good chunky volume too

[blackrabbit] 30/4/2007 17:26

To think that these were around 24p less than 2 years ago.........11p now seems too good a bargain to miss. BR.

[felix99] 30/4/2007 09:20

yes its building up nicely. If those ranges are launching well I think we will see a trading ahead statement in next month or two. DAn commment last week said ranges were going to mgt expectations so assuming they have actually spoken to management it bodes well imho.

Some of the overhang clearing as well imho. Lets see SCAP on the bid and thn we know the stock has cleared.

Better buy whilst there is stock around cos quote size is 10k and you won;t get any for love nor money when a +ve trading statmeent hits - well not at these prices anyway !

[cockneyrebel] 30/4/2007 08:23

punters about to go nutty for NUT imo Felix :-)

CR

[felix99] 19/4/2007 16:25

all on PLus Homewell



About 400k went through in total 17th think it was between the two. Still stock at 10p alas .

Yuo will find when you have 5000 posts a day on a BB the stock ends up full of traders and crazies. when its quiet the discerning investor who has done some research are on board. So if you do your research and find the BB quiet that means by the time the rest of the world has found out you will be sitting on a nice gain.

[homewell] 18/4/2007 19:38

oh yes, the signs of a great long term stock? No massive ADVFN BB!!!! LOL!

Interesting that some purchases aren't showing though...

[felix99] 18/4/2007 17:06

I bought some more today too CR. Looks a cracker if Champneys and Travelguard go as expected.

Be an interesting next few months. I have done all the research and if the ranges move well and quick they will shatter EPS forecasts of 1p put out by Daniel Stewart.

If they move slower than expected then first half figs could be a bit dull and this year will be second half weighted.

All looks kosher - hopefully the launch of Champneys stuff will get a good right up in the glossy mags etc and if Posh or someone is seen with the stuff then watch it rocket - and the share price too.

Oh yes and a nice quiet BB - its a cracker I tellya

[cockneyrebel] 18/4/2007 15:58

Nice trading statement, very low fwd PE, director buying.

Looks a buy to me so I did yesterday :-)

Seem to have lots of products being well received and the outlets increasing too.

imo, dyor.

CR

[atlantic1953] 16/3/2007 13:17

Yes but zero impact on the share price

[homewell] 15/3/2007 19:48

and another late trade...

[homewell] 15/3/2007 14:48

another big buy (340k) to add to the director purchase last week?

[mattyfromtheblock] 24/1/2007 11:08

NeutraHealth Plc
24 January 2007


24 January 2007


NEUTRAHEALTH PLC


ACQUISITION OF BRUNEL HEALTHCARE LIMITED


NeutraHealth plc, which was admitted to trading on AIM in February 2005 to
acquire companies in the Nutraceutical industry, today announces the acquisition
of the entire issued share capital of Brunel Healthcare Limited ('Brunel'), an
established supplier of nutraceutical products and over the counter ('OTC')
medicines which are currently sold by major retailers across the UK.

The £4 million initial purchase price will be funded by an increased debt
facility with existing bankers KBC Bank NV. The £4 million initial
consideration, combined with Brunel's existing debt of £0.96m, represents an
acquisition multiple of 6.8 x EBITDA (pre exceptional items) for the year ending
31 December 2006 (unaudited). Additionally, vendors may receive up to £1.9
million further consideration through an earn-out under the conditions
summarized below. The acquisition of Brunel is classified as a 'substantial
transaction' pursuant to Rule 12 of the AIM Rules.

Brunel distributes private label and branded vitamins & supplements, and OTC
medicines to major national accounts. Branded products include the Vertese range
of gelatin free supplements, Sambucol Elderberry and Brunel Healthcare branded
analgesic ranges. Vertese and other brands are distributed through Alliance
Boots, Tesco, Holland & Barrett, Superdrug, Waitrose and others.

Brunel has demonstrated sustained sales growth since 2001, achieving nearly 50%
growth in turnover between 2003 and 2006, from £9.5m to £14.0 million, and more
than 240% increase in EBITDA between 2003 and 2006 from £302,000 to £728,000.
This has been achieved by building strong customer relationships through
providing first class service and operational excellence.

This is the third acquisition for NeutraHealth in less than two years and
complements the existing Group by providing instant and extensive access to a
wide retail distribution network. This comes on the back of recent announcements
by NeutraHealth regarding the launch of the TravelGuard and Champneys product
ranges. Nationwide distribution has already been agreed for TravelGuard and
negotiations are ongoing with major retailers for UK roll out of Champneys'
vitamins and supplements later this year. Securing a cornerstone business in the
'multiple retailers' channel will help maximise the potential of these brands.

Further group synergies such as supply chain optimisation, the sharing of
technical expertise and combined export initiatives promises to create a very
solid platform for growth in 2007 and beyond.

Martin Gatto, NeutraHealth Chairman, commented:

'I am particularly pleased to see this acquisition concluding at this time.
During 2006 we have developed a platform for expansion. We have started 2007
with success in agreeing the launch of the Champneys range of supplements, and
now we have agreed a cornerstone acquisition. We are delivering our strategy of
growing existing businesses and driving future industry consolidation. The
prospects for growth in 2007 look good and I am optimistic about the year
ahead.'


Michael Toxvaerd, NeutraHealth Chief Executive, commented:

'Brunel Healthcare is a well run company that is respected in our industry, and
I am delighted that we have secured a business that complements the existing
group. This allows us to deliver synergies across different distribution
channels and maximise growth opportunities in 2007 and beyond.'


Acquisition Summary

•Initial consideration of £4 million, payable in cash for 100% of share
capital of Brunel Healthcare Limited

• Debt facility arranged with KBC Bank NV : £5 million five year term loan
plus £3.5 million revolver loan, replacing existing facility

• Brunel founding shareholder and director Ron Stagg, and fellow
shareholder and director Peter Hodgkiss to remain with the business.

• Earn out consideration is available as follows:

- For 2007, up to £0.8 million on attaining greater than 30% PBIT
growth from 2006 levels
- For 2008, up to £1.1 million on attaining greater than 70% PBIT
growth from 2006 levels
- The consideration is calculated pro-rata on performance, with 25%
payable in shares at NeutraHealth's discretion
- The earn out may be extended into 2009 with reduced consideration
payable


Summary Financials (2006 unaudited) for Brunel Healthcare Limited

• EBITDA pre exceptional costs for year ended 31 December 2006 : £0.73
million (2005 : £0.6 million)

• Sales for year ended 31 December 2006 : £14.0 million (2005 : £13.3
million)

• PBIT for year ended 31 December 2006 : £0.55 million (2005 : 0.3
million)

• PBT for year ended 31 December 2006 : £0.48 million (2005 : £0.2
million)

• Net Assets at 31 December 2006 : £0.70 million (2005 : £0.44 million)

• Net Debt at 31 December 2006 : £0.96 million (2005 : £1.0 million)


For more information:

NeutraHealth plc
Martin Gatto, Chairman 07778 749 223
Michael Toxvaerd, Chief Executive 07730 581 584
Robin Hilton, Finance Director 07738 018 411

KBC Peel Hunt
Matt Goode 020 7418 8900

Pelham Public Relations
James Henderson 020 7743 6672
Gavin Davis 020 7743 6677


Further information for investors is available on the Company's website at

www.neutrahealthplc.com/

[atlantic1953] 20/1/2007 18:25

Prospects seem good and the directors well motivated via share options, however the share price preformance remains poor.

[mattyfromtheblock] 17/1/2007 21:03

Looks like a good agreement for NUT today. Getting thier products some more exposure with a well known company. Still looking good.

[mattyfromtheblock] 17/1/2007 21:01

NeutraHealth Plc
17 January 2007


17 January 2007


NEUTRAHEALTH PLC ('the Company')


LICENSING AGREEMENT WITH CHAMPNEYS SPA GROUP


NeutraHealth is pleased to announce the signing of an exclusive licensing
agreement with the Champneys Spa Group, leading to the launch of a new health
and beauty range of vitamins and supplements sold through major retail outlets
under the Champneys name.

The Champneys range has been designed by the experienced NeutraHealth technical
team, leveraging many of the market leading product technologies already in use
within the group. The breadth of products, including multivitamins, essential
fatty acids, probiotics and other specialist solutions such as Busy Lifestyle
Support, Skin Support and Hair & Nail, provides users with a solution for most
of their supplemental needs. The range will be used by health practitioners
within Champneys' spas, and negotiations are ongoing with major retailers for
roll-out across the country later in the year.

NeutraHealth is now positioned to capitalise on the emerging trend of consumers
paying attention to inner health in order to improve outward appearance. There
is a strong synergy with Champneys, who launched a range of beauty products at
the end of 2004 and have achieved successful national distribution in
Sainsbury's. The Champneys brand is being revitalised, with £14m invested in
its flagship resort in Tring, and the opening of its first day spa and retail
outlet in Chichester, with 20 more openings planned for this year. 'We are a
wellbeing brand now, not just a destination,' says Champneys Managing Director,
Stephen Purdew.

In December, NeutraHealth announced the launch of the TravelGuard suite of
consumer products. This range is now available in the NutriCentre, Farmacia and
other selected retailers. The Champneys and TravelGuard ranges create the first
material benefits of NeutraHealth's expansion into the consumer segment and the
Company expects more developments as 2007 unfolds.

As reported in December, autumn sales returned to expected levels after a
disappointing summer. The sales initiatives implemented mid year are maturing
and delivering increases in customer numbers and sales. This upward trend has
seen the Company deliver sales in line with expectations for 2006 and the trend
is expected to continue.


Michael Toxvaerd, NeutraHealth Chief Executive, commented:

'We believe this agreement with Champneys will build value for both businesses,
as well as meeting the growing demand for quality brands in the marketplace. We
are very happy to be working with such a well-respected health and beauty brand
and believe that our specific technical and commercial expertise fits very
well.


We ended 2006 with sales in line with expectations for the year. This agreement
is a great start to 2007, and we are confident about the prospects of
NeutraHealth in the year ahead.'



For more information:

Further information for investors is available on the Company's website at

www.neutrahealthplc.com/


NeutraHealth plc
Martin Gatto, Chairman 07778 749 223
Michael Toxvaerd, Chief Executive 07730 581 584
Robin Hilton, Finance Director 07738 018 411

KBC Peel Hunt
Matt Goode 020 7418 8900

Pelham Public Relations
James Henderson 020 7743 6672
Gavin Davis